Gilead Sciences (GILD) Misses Q2 EPS by 34c; Guides In-Line
Get Alerts GILD Hot Sheet
Price: $146.85 +1.82%
EPS Growth %: -14.2%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -14.2%
Financial Fact:
Total costs and expenses: 3.1B
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.11, $0.34 worse than the analyst estimate of $1.45. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.31 billion.
GUIDANCE:
Gilead Sciences sees FY2020 EPS of $6.25-$7.65, versus the consensus of $6.71. Gilead Sciences sees FY2020 revenue of $23-25 billion, versus the consensus of $23.44 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Gilead Sciences (GILD) PT Raised to $158 at Truist Securities
- Gilead Sciences (GILD) PT Raised to $170 at JPMorgan
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share